RT Journal Article
T1 Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii.
A1 Blasco, Lucia
A1 Ambroa, Anton
A1 Lopez, Maria
A1 Fernandez-Garcia, Laura
A1 Bleriot, Ines
A1 Trastoy, Rocio
A1 Ramos-Vivas, Jose
A1 Coenye, Tom
A1 Fernandez-Cuenca, Felipe
A1 Vila, Jordi
A1 Martinez-Martinez, Luis
A1 Rodriguez-Baño, Jesus
A1 Pascual, Alvaro
A1 Cisneros, Jose Miguel
A1 Pachon, Jeronimo
A1 Bou, German
A1 Tomas, Maria
K1 Acinetobacter baumannii
K1 Antibiotic-phage synergy
K1 Multiresistant
K1 Mutant lytic phage
K1 Phage therapy
AB Phage therapy is an abandoned antimicrobial therapy that has been resumed in recent years. In this study, we mutated a lysogenic phage from cinetobacter baumannii into a lytic phage (Ab105-2phi∆CI) that displayed antimicrobial activity against A. baumannii clinical strain Ab177_GEIH-2000 (isolated in the GEIH-REIPI Spanish Multicenter A. baumannii Study II 2000/2010, Umbrella Genbank Bioproject PRJNA422585, and for which meropenem and imipenem MICs of respectively, 32 µg/mL, and 16 µg/mL were obtained). We observed an in vitro synergistic antimicrobial effect (reduction of 4 log–7 log CFU/mL) between meropenem and the lytic phage in all combinations analyzed (Ab105-2phi∆CI mutant at 0.1, 1 and 10 MOI and meropenem at 1/4 and 1/8 MIC). Moreover, bacterial growth was reduced by 8 log CFU/mL for the combination of imipenem at 1/4 MIC plus lytic phage (Ab105-2phi∆CI mutant) and by 4 log CFU/mL for the combination of imipenem at 1/8 MIC plus lytic phage (Ab105-2phi∆CI mutant) at both MOI 1 and 10. These results were confirmed in an in vivo model (G. mellonella), and the combination of imipenem and mutant Ab105-2phi∆CI was most effective (p < 0.05). This approach could help to reduce the emergence of phage resistant bacteria and restore sensitivity to antibiotics used to combat multi-resistant strains of Acinetobacter baumannii.
PB MDPI
SN 2076-2607
YR 2019
FD 2019-11-09
LK http://hdl.handle.net/10668/14690
UL http://hdl.handle.net/10668/14690
LA en
NO Blasco L, Ambroa A, Lopez M, Fernandez-Garcia L, Bleriot I, Trastoy R, et al. Combined Use of the Ab105-2φΔCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii. Microorganisms. 2019 Nov 12;7(11):556
DS RISalud
RD Jul 2, 2025